Cocrystal Doses First Patient in Norovirus Trial
by Press Release from Outbreak News Today on (#6F5FP)
NewsDesk@bactiman63 Cocrystal Pharma announced the of the first subjects in a Phase 1 clinical trial with its oral, first-in-class pan-norovirus and pan-coronavirus 3CL protease inhibitor CDI-988. This pan-viral protease inhibitor was discovered using the Company's proprietary structure-based drug discovery platform technology. The Phase 1 study will evaluate the safety, tolerability and pharmacokinetics of oral CDI-988 [...]
The post Cocrystal Doses First Patient in Norovirus Trial appeared first on Outbreak News Today.